J&J reports data from Phase II/III ENERGY trial for wAIHA

J&J has reported the first outcomes from the Phase II/III ENERGY trial indicating that Imaavy led to significant Hgb improvement in patients with wAIHA. The study found the 30mg/kg nipocalimab group had a statistically significant durable haemoglobin response by week 24. Patients treated with nipocalimab also saw nearly two-thirds achieving both Hgb ≥10g/dL and a ≥2g/dL rise from baseline by week 24. Credit: Sai Thaw Kyar / Shutterstock.com. Johnson & Johnson (J&J) has reported the first outcomes from the Phase II/III ENERGY trial, indicating that Imaavy (nipocalimab-aahu) led to a significant haemoglobin (Hgb) improvement in patients with warm autoimmune haemolytic…

Source: Clinical Trials Arena